These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29028155)

  • 1. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
    Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
    Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
    Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
    Yin GN; Lee HW; Cho JY; Suk K
    Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
    Hendrickson RC; Lee AY; Song Q; Liaw A; Wiener M; Paweletz CP; Seeburger JL; Li J; Meng F; Deyanova EG; Mazur MT; Settlage RE; Zhao X; Southwick K; Du Y; Holder D; Sachs JR; Laterza OF; Dallob A; Chappell DL; Snyder K; Modur V; King E; Joachim C; Bondarenko AY; Shearman M; Soper KA; Smith AD; Potter WZ; Koblan KS; Sachs AB; Yates NA
    PLoS One; 2015; 10(8):e0135365. PubMed ID: 26270474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard.
    Zhou M; Duong DM; Johnson ECB; Dai J; Lah JJ; Levey AI; Seyfried NT
    J Proteome Res; 2019 Jun; 18(6):2422-2432. PubMed ID: 30983353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.
    Sathe G; Na CH; Renuse S; Madugundu AK; Albert M; Moghekar A; Pandey A
    Proteomics Clin Appl; 2019 Jul; 13(4):e1800105. PubMed ID: 30578620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
    Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
    EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
    Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
    PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study.
    Russell CL; Heslegrave A; Mitra V; Zetterberg H; Pocock JM; Ward MA; Pike I
    Rapid Commun Mass Spectrom; 2017 Jan; 31(2):153-159. PubMed ID: 27813239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
    Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
    J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
    Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
    Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
    J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.
    Öhrfelt A; Brinkmalm A; Dumurgier J; Brinkmalm G; Hansson O; Zetterberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2016 Oct; 8(1):41. PubMed ID: 27716408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease.
    Park SA; Jung JM; Park JS; Lee JH; Park B; Kim HJ; Park JH; Chae WS; Jeong JH; Choi SH; Baek JH
    Sci Rep; 2020 May; 10(1):7423. PubMed ID: 32366888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.
    Castaño EM; Roher AE; Esh CL; Kokjohn TA; Beach T
    Neurol Res; 2006 Mar; 28(2):155-63. PubMed ID: 16551433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.